{"id":436,"date":"2022-02-01T20:25:55","date_gmt":"2022-02-01T19:25:55","guid":{"rendered":"https:\/\/porphyria.network\/IPPN\/?p=436"},"modified":"2022-02-01T20:32:01","modified_gmt":"2022-02-01T19:32:01","slug":"afamelanotide-permanently-reimbursed-good-news-from-germany","status":"publish","type":"post","link":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/","title":{"rendered":"Afamelanotide: Good News from Germany!"},"content":{"rendered":"\n<p>Afamelanotide (Scenesse \u00ae) will continue to be available for the treatment of adult patients with EPP in Germany, where the drug has been initially evaluated in 2016, resulting in a positive recommendation for reimbursement. However, the competent national authority \u201cFederal Joint Committee\u201d at that time decided to re-evaluate afamelanotide in 2021, because more data on the safety and effectiveness of afamelanotide were expected to become available. Now, the second evaluation confirmed the initial assessment but this time, the positive recommendation is permanent. The outcome of the re-evaluation is also Good News for patients living in Switzerland and Austria, where reimbursement is still based on individual decisions by health insurers and other payers, which frequently take assessments of other countries like Germany into consideration.&nbsp;<\/p>\n\n\n\n<p><strong>Pharmaceutical Directive\/Annex XII: Afamelanotide (Reassessment after the deadline: Phototoxicity in erythropoietic protoporphyria (EPP))<\/strong><br><a href=\"https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/636\/#english\">https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/636\/#english<\/a> <br>(last accessed 31 January 2022)<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Afamelanotide (Scenesse \u00ae) will continue to be available for the treatment of adult patients with EPP in Germany, where the drug has been initially evaluated in 2016, resulting in a positive recommendation for reimbursement. However, the competent national authority \u201cFederal Joint Committee\u201d at that time decided to re-evaluate afamelanotide in 2021, because more data on&hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[31],"tags":[42,44,43,45,46],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.6.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Afamelanotide: Good News from Germany! - International Porphyria Patient Network<\/title>\n<meta name=\"description\" content=\"International Porphyria Patient Network Afamelanotide Federal Joint Committee Germany Protoporphyria Reimbursement\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Afamelanotide: Good News from Germany! - International Porphyria Patient Network\" \/>\n<meta property=\"og:description\" content=\"International Porphyria Patient Network Afamelanotide Federal Joint Committee Germany Protoporphyria Reimbursement\" \/>\n<meta property=\"og:url\" content=\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/\" \/>\n<meta property=\"og:site_name\" content=\"International Porphyria Patient Network\" \/>\n<meta property=\"article:published_time\" content=\"2022-02-01T19:25:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-02-01T19:32:01+00:00\" \/>\n<meta name=\"author\" content=\"Editorial Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Editorial Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/\"},\"author\":{\"name\":\"Editorial Team\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\"},\"headline\":\"Afamelanotide: Good News from Germany!\",\"datePublished\":\"2022-02-01T19:25:55+00:00\",\"dateModified\":\"2022-02-01T19:32:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/\"},\"wordCount\":150,\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"keywords\":[\"Afamelanotide\",\"Federal Joint Committee\",\"Germany\",\"Protoporphyria\",\"Reimbursement\"],\"articleSection\":[\"English\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/\",\"name\":\"Afamelanotide: Good News from Germany! - International Porphyria Patient Network\",\"isPartOf\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\"},\"datePublished\":\"2022-02-01T19:25:55+00:00\",\"dateModified\":\"2022-02-01T19:32:01+00:00\",\"description\":\"International Porphyria Patient Network Afamelanotide Federal Joint Committee Germany Protoporphyria Reimbursement\",\"breadcrumb\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/porphyria.network\/IPPN\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Afamelanotide: Good News from Germany!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#website\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"name\":\"International Porphyria Patient Network\",\"description\":\"Welcome to the International Porphyria Patient Network\",\"publisher\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#organization\",\"name\":\"International Porphyria Patient Network\",\"url\":\"https:\/\/porphyria.network\/IPPN\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"contentUrl\":\"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif\",\"width\":671,\"height\":630,\"caption\":\"International Porphyria Patient Network\"},\"image\":{\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765\",\"name\":\"Editorial Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g\",\"caption\":\"Editorial Team\"},\"url\":\"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Afamelanotide: Good News from Germany! - International Porphyria Patient Network","description":"International Porphyria Patient Network Afamelanotide Federal Joint Committee Germany Protoporphyria Reimbursement","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/","og_locale":"en_US","og_type":"article","og_title":"Afamelanotide: Good News from Germany! - International Porphyria Patient Network","og_description":"International Porphyria Patient Network Afamelanotide Federal Joint Committee Germany Protoporphyria Reimbursement","og_url":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/","og_site_name":"International Porphyria Patient Network","article_published_time":"2022-02-01T19:25:55+00:00","article_modified_time":"2022-02-01T19:32:01+00:00","author":"Editorial Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Editorial Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/#article","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/"},"author":{"name":"Editorial Team","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765"},"headline":"Afamelanotide: Good News from Germany!","datePublished":"2022-02-01T19:25:55+00:00","dateModified":"2022-02-01T19:32:01+00:00","mainEntityOfPage":{"@id":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/"},"wordCount":150,"publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"keywords":["Afamelanotide","Federal Joint Committee","Germany","Protoporphyria","Reimbursement"],"articleSection":["English"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/","url":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/","name":"Afamelanotide: Good News from Germany! - International Porphyria Patient Network","isPartOf":{"@id":"https:\/\/porphyria.network\/IPPN\/#website"},"datePublished":"2022-02-01T19:25:55+00:00","dateModified":"2022-02-01T19:32:01+00:00","description":"International Porphyria Patient Network Afamelanotide Federal Joint Committee Germany Protoporphyria Reimbursement","breadcrumb":{"@id":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/porphyria.network\/IPPN\/2022\/02\/afamelanotide-permanently-reimbursed-good-news-from-germany\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/porphyria.network\/IPPN\/"},{"@type":"ListItem","position":2,"name":"Afamelanotide: Good News from Germany!"}]},{"@type":"WebSite","@id":"https:\/\/porphyria.network\/IPPN\/#website","url":"https:\/\/porphyria.network\/IPPN\/","name":"International Porphyria Patient Network","description":"Welcome to the International Porphyria Patient Network","publisher":{"@id":"https:\/\/porphyria.network\/IPPN\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/porphyria.network\/IPPN\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/porphyria.network\/IPPN\/#organization","name":"International Porphyria Patient Network","url":"https:\/\/porphyria.network\/IPPN\/","sameAs":[],"logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/","url":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","contentUrl":"https:\/\/porphyria.network\/IPPN\/wp-content\/uploads\/2019\/06\/IPPN-logo-2019.gif","width":671,"height":630,"caption":"International Porphyria Patient Network"},"image":{"@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/81925e7a7e198769c7d37b3623015765","name":"Editorial Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/porphyria.network\/IPPN\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3ec564d1f50ebaa304b1393eb7241f76?s=96&d=mm&r=g","caption":"Editorial Team"},"url":"https:\/\/porphyria.network\/IPPN\/author\/editorial-team\/"}]}},"_links":{"self":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/436"}],"collection":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/comments?post=436"}],"version-history":[{"count":3,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/436\/revisions"}],"predecessor-version":[{"id":439,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/posts\/436\/revisions\/439"}],"wp:attachment":[{"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/media?parent=436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/categories?post=436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/porphyria.network\/IPPN\/wp-json\/wp\/v2\/tags?post=436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}